Natus Medical (NASDAQ:BABY) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Saturday.
Separately, Zacks Investment Research raised shares of Natus Medical from a “hold” rating to a “buy” rating and set a $45.00 price target on the stock in a research report on Tuesday, October 24th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. Natus Medical has a consensus rating of “Hold” and an average price target of $46.50.
Natus Medical (NASDAQ:BABY) opened at $37.60 on Friday. The firm has a market capitalization of $1,171.39, a P/E ratio of 24.26 and a beta of 0.84. Natus Medical has a twelve month low of $31.65 and a twelve month high of $43.60. The company has a current ratio of 4.21, a quick ratio of 3.36 and a debt-to-equity ratio of 0.36.
Natus Medical (NASDAQ:BABY) last issued its earnings results on Wednesday, October 25th. The medical equipment provider reported $0.40 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.38 by $0.02. The business had revenue of $122.60 million for the quarter, compared to analysts’ expectations of $122.41 million. Natus Medical had a positive return on equity of 12.06% and a negative net margin of 0.62%. The business’s revenue for the quarter was up 34.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.39 EPS. research analysts predict that Natus Medical will post 1.74 earnings per share for the current year.
In other news, Director William M. Moore sold 5,000 shares of Natus Medical stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $41.01, for a total transaction of $205,050.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Robert A. Gunst sold 4,400 shares of Natus Medical stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $35.17, for a total transaction of $154,748.00. Following the sale, the director now directly owns 50,850 shares in the company, valued at approximately $1,788,394.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 22,042 shares of company stock worth $902,266. Corporate insiders own 5.50% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in BABY. Benjamin F. Edwards & Company Inc. raised its position in Natus Medical by 2,085.6% in the third quarter. Benjamin F. Edwards & Company Inc. now owns 2,732 shares of the medical equipment provider’s stock valued at $102,000 after purchasing an additional 2,607 shares during the period. Riverhead Capital Management LLC raised its position in Natus Medical by 90.9% in the second quarter. Riverhead Capital Management LLC now owns 2,864 shares of the medical equipment provider’s stock valued at $107,000 after purchasing an additional 1,364 shares during the period. Sei Investments Co. raised its position in Natus Medical by 29.7% in the second quarter. Sei Investments Co. now owns 3,182 shares of the medical equipment provider’s stock valued at $119,000 after purchasing an additional 728 shares during the period. SG Americas Securities LLC purchased a new stake in Natus Medical in the third quarter valued at approximately $138,000. Finally, Victory Capital Management Inc. raised its position in Natus Medical by 17.6% in the second quarter. Victory Capital Management Inc. now owns 3,744 shares of the medical equipment provider’s stock valued at $140,000 after purchasing an additional 560 shares during the period. 94.39% of the stock is currently owned by institutional investors.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.